FY2024 Earnings Forecast for MAZE Issued By Leerink Partnrs

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Research analysts at Leerink Partnrs issued their FY2024 EPS estimates for Maze Therapeutics in a report issued on Tuesday, February 25th. Leerink Partnrs analyst J. Schwartz anticipates that the company will earn ($4.93) per share for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Maze Therapeutics’ Q4 2024 earnings at ($7.60) EPS, Q1 2025 earnings at ($0.58) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($2.07) EPS, FY2026 earnings at ($2.63) EPS, FY2027 earnings at ($2.52) EPS, FY2028 earnings at ($2.72) EPS and FY2029 earnings at ($3.17) EPS.

A number of other brokerages have also weighed in on MAZE. Leerink Partners initiated coverage on Maze Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $28.00 price objective on the stock. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research report on Tuesday. Guggenheim began coverage on shares of Maze Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $19.00 price target for the company. Finally, JPMorgan Chase & Co. initiated coverage on Maze Therapeutics in a report on Tuesday. They issued an “overweight” rating and a $30.00 price objective for the company. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $25.67.

Maze Therapeutics Stock Up 8.7 %

MAZE stock opened at $12.72 on Thursday. Maze Therapeutics has a 1 year low of $10.08 and a 1 year high of $17.00.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.